PROLOR Biotech To Present New Data On Its Long-Acting Human Growth Hormone And Long-Acting Oxyntomodulin At ENDO 2013

SAN FRANCISCO and NES-ZIONA, Israel, June 13, 2013 /PRNewswire/ --PROLOR Biotech, Inc. (NYSE MKT: PBTH), today announced that the company will present new data on its long-acting human growth hormone (hGH-CTP) in Phase III development for the treatment of growth hormone deficiency and its long acting oxyntomodulin (MOD-6030) in preclinical development for the treatment of obesity and type 2 diabetes at ENDO 2013, the 95th Annual Meeting of the Endocrine Society.

PROLOR's scientists will present additional pre-clinical and clinical safety data on hGH-CTP and will discuss its manufacturing process. Data previously reported by the company confirmed that hGH-CTP appears to be safe and well tolerated and that it has the potential to be administered once-weekly to adults with growth hormone deficiency. The new data provides further information on the excellent safety and tolerability profile of hGH-CTP in a variety of pre-clinical and clinical studies. PROLOR recently announced that it has initiated a pivotal Phase III study of hGH-CTP in growth hormone deficient adults.

In addition, PROLOR scientists will make an oral presentation discussing MOD-6030, also known as LA-Oxyntomodulin, the company's long-acting GLP-1 and Glucagon dual agonist with potential for the treatment of type 2 diabetes and obesity. New pre-clinical data will be presented on MOD-6030's effects on weight reduction and glucose tolerance in animal models.

The PROLOR presentations include the following:

FP02-3: The Long-Acting Dual GLP-1/Glucagon Agonist, Mod-6030, Improves Glycemic Control and Induces a Prolonged Weight Loss in Diet-Induced Obesity Mice Following a Once-Weekly Administration. See abstract for more information.

SAT-120: Metabolic and Safety Parameters of Once-Weekly, CTP-Modified Human Growth Hormone (MOD-4023): Results of a Phase 2 Dose and Frequency Finding Study. See abstract for more information.

SAT-644: Pre-clinical Characterization of MOD-4023, a Long-Acting Growth Hormone. See abstract for more information.

SAT-647: Highly Producing Fed-Batch Manufacturing Process of Long-Acting Human Growth Hormone (MOD-4023) in CHO Cells. See abstract for more information.

SUN-637: Development of a Population Pharmacokinetic and Pharmacodynamic Model Following a Phase II Study of MOD-4023 in Growth Hormone Deficient Adults. See abstract for more information.

ENDO 2013 abstracts are available online at: https://endo.confex.com/endo/2013endo/webprogram/COP.html.

Read the rest here:
PROLOR Biotech To Present New Data On Its Long-Acting Human Growth Hormone And Long-Acting Oxyntomodulin At ENDO 2013